Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
03/2012
03/01/2012WO2012027514A2 Compositions and methods for cardiac therapy
03/01/2012WO2012027494A1 Bispecific targeting reagents
03/01/2012WO2012027204A1 End-capped polymers
03/01/2012WO2012026609A1 Aqueous composition for ophthalmic administration
03/01/2012WO2012026562A1 Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
03/01/2012WO2012026533A1 Hydrogel laminate, method for producing hydrogel laminate, and hydrogel
03/01/2012WO2012026499A1 Storage method and stabilizing agent for aspartyl dipeptide ester derivative
03/01/2012WO2012026316A1 Switching fluorescent nanoparticle probe and fluorescent particle imaging method using same
03/01/2012WO2012025745A1 Glycodendrimers of polypropyletherimine
03/01/2012WO2012025744A1 Glycodendrimers of polypropyletherimine
03/01/2012WO2012025624A1 Processes for producing microporous silica materials
03/01/2012WO2012025551A1 Porous degradable polyelectrolyte microspheres as vaccine vector
03/01/2012WO2012025514A1 Antimicrobial nanoparticle conjugates
03/01/2012WO2012024785A1 Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions
03/01/2012WO2012003398A8 Protein precursors as prodrugs
03/01/2012WO2011161531A4 Pharmaceutical composition containing goserelin for in-situ implant
03/01/2012WO2011154349A3 Fgf21 analogues and derivatives
03/01/2012WO2011151704A3 Stable pharmaceutical compositions of rapamycin esters
03/01/2012WO2011140236A3 Triamcinolone acetonide formulations for treating dermatitis and psoriasis
03/01/2012WO2011139044A3 Controlled-release pharmaceutical composition including tamsulosin or the pharmaceutically acceptable salts thereof, and oral preparation including same
03/01/2012WO2011137228A3 Composition and method for treating eustachian tube dysfunction
03/01/2012WO2011135461A3 Clay compositions
03/01/2012WO2011125015A3 Protease-activatable pore-forming polypeptides
03/01/2012WO2011121560A3 Stabilized antibody preparations and uses thereof
03/01/2012WO2011109809A3 A novel composition of matter for delivering lipid-soluble materials, and a method for producing it
03/01/2012WO2011109334A3 Localization of agents at a target site with a composition and an energy source
03/01/2012WO2011108826A3 Complex formulation for oral administration comprising probiotic formulation and 5-ht4 receptor agonist and method for the preparation thereof
03/01/2012WO2011098518A3 Delivery of immunoglobulin variable domains and constructs thereof
03/01/2012WO2011095801A3 Liquid pharmaceutical composition for buccal administration comprising morphine
03/01/2012WO2011076207A3 Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
03/01/2012WO2011064271A3 Use of an oleo gel containing triterpene for healing wounds
03/01/2012WO2011053989A3 Process of transfection of mutagenic and recombinant nucleic acids to cells by polymeric materials loaded therewith
03/01/2012WO2011051354A3 Transdermal pharmaceutical compositions comprising active agents
03/01/2012US20120053252 Fluorinated ethoxylated polyurethanes
03/01/2012US20120053251 Fat emulsion providing improved health and taste characteristics in food
03/01/2012US20120053250 Polymer shells
03/01/2012US20120053249 Compressible and free-flow co-agglomerates of mannitol and granular starch
03/01/2012US20120053248 Solid Pharmaceutical Preparations Containing Copolymers Based On Polyethers Combined With Poorly Water-Soluble Polymers
03/01/2012US20120053233 Gene transfer agent composition containing polyamidoamine dendron
03/01/2012US20120053219 Processes of making and using pharmaceutical formulations of antineoplastic agents
03/01/2012US20120053163 Steroids as Agonists for FXR
03/01/2012US20120053156 Compositions and methods for loop diuretics with consistent bioavailability
03/01/2012US20120053145 Aripiprazole complex formulation and method
03/01/2012US20120053058 Particles comprising a biopolymer which is degradable under the effect of an electromagnetic wave as emitted by a solar radiation
03/01/2012US20120052515 Therapeutic applications of noncovalent dimerizing antibodies
03/01/2012US20120052292 Novel medical device coatings
03/01/2012US20120052097 Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
03/01/2012US20120052068 Autophilic antibodies and method of making the same
03/01/2012US20120052041 Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
03/01/2012US20120052023 Controlled release active agent carrier
03/01/2012US20120052015 End-capped polymers
03/01/2012CA2809433A1 Dual variable domain immunoglobulins and uses thereof
03/01/2012CA2808975A1 Stable formulations of neisseria meningitidis rlp2086 antigens
03/01/2012CA2808872A1 Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions
03/01/2012CA2808539A1 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
03/01/2012CA2808225A1 Compositions and methods for cardiac therapy
03/01/2012CA2796755A1 Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
02/2012
02/29/2012EP2423335A2 Chimeric immunomodulatory compounds and methods of using the same
02/29/2012EP2423291A1 1-menthyl (3r)-3-hydroxybutanoate, process for producing same, and composition containing same for stimulating sense
02/29/2012EP2423290A1 Process for producing 1-menthyl (3s)-3-hydroxybutanoate and composition for stimulating sense
02/29/2012EP2423223A1 Novel exendin variant and conjugate thereof
02/29/2012EP2422818A2 Process to produce a diclofenac cyclodextrin conjugate
02/29/2012EP2422817A1 Flavin-nucleic acid ligand conjugates
02/29/2012EP2422816A1 A drug composition for treating tumor with polymeric micelle encapsulating antineoplastic
02/29/2012EP2422809A1 Novel vaccine formulations
02/29/2012EP2422804A1 Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers
02/29/2012EP2422792A1 Electrochemically activated aqueous solution and use of the solution
02/29/2012EP2422783A1 Pharmaceutical Composition
02/29/2012EP2422770A1 Formulations of peg-interferon alpha conjugates
02/29/2012EP2422766A2 Methods for preparing dry powder compositions of glycopyrrolate
02/29/2012EP2422765A1 Ophthalmic compositions and methods for treating eyes
02/29/2012EP2421880A1 Nucleic acid delivery compositions and methods
02/29/2012EP2421562A1 Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
02/29/2012EP2421561A2 Immunonanotherapeutics providing a th1-biased response
02/29/2012EP2421560A2 Delivery systems
02/29/2012EP2421551A2 Silk fibroin hydrogels and uses thereof
02/29/2012EP2421545A1 Method and composition for synchronizing time of insemination
02/29/2012EP2421531A1 Use of nifuratel to treat infections caused by atopobium species
02/29/2012EP2421529A2 Siderophore conjugate immunogenic compositions and vaccines
02/29/2012EP2421522A1 Paracetamol for parenteral administration
02/29/2012EP2421520A1 Pharmaceutical compositions for the treatment of nasal polyposis
02/29/2012EP2421517A2 Controlled release dispensing device
02/29/2012EP2421505A2 Hydrogels for combinatorial delivery of immune-modulating biomolecules
02/29/2012EP2421494A2 Method for producing free powder particles of polyamide impregnated with at least one cosmetic or pharmaceutical agent, and free powder particles of polyamide having a content of at least 25 wt % of at least one cosmetic or pharmaceutical agent
02/29/2012EP2048948B1 Liquid compositions of calcium acetate
02/29/2012EP2010221B1 Antibody-rnase-conjugate
02/29/2012EP1740213B1 Liquid growth hormone formulation
02/29/2012EP1735005B1 Method for encapsulation of orally ingested materials to alter the site of digestion, site of action, or stability
02/29/2012EP1641487B1 Liquid composition of factor vii polypeptides
02/29/2012EP1633800B9 Polyamino acids functionalised with at least one hydrophobic group and applications thereof particularly therapeutic applications
02/29/2012EP1625850B1 Immunostimulating agents
02/29/2012EP1480677B1 Composition for stabilizing hyaluronic acid
02/29/2012EP1390383B1 Antisense permeation enhancers
02/29/2012CN1921888B Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same
02/29/2012CN1842325B Dosage form
02/29/2012CN1447698B Flavone-containing plant extract solutions having improved storage and head stability
02/29/2012CN102365290A Method for producing sugar composition containing definite amount of target hexose and having sugar composition ratio different from starting sugar material, and use of sugar composition thus produced
02/29/2012CN102365099A Bonding products of aminated polysaccharides
02/29/2012CN102365098A Finely pulverized pharmaceutical composition
02/29/2012CN102365092A Burdock fruit extract containing arctigenin at high content and process for producing same
1 ... 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 ... 1712